Literature DB >> 24028214

Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.

Young Eun Chon1, Kyu Sik Jung, Seung Up Kim, Jun Yong Park, Young Nyun Park, Do Young Kim, Sang Hoon Ahn, Chae Yoon Chon, Hye Won Lee, Yehyun Park, Kwang-Hyub Han.   

Abstract

BACKGROUND: Controlled attenuation parameter (CAP) is a non-invasive method of measuring hepatic steatosis using a process based on transient elastography. We investigated the diagnostic accuracy of CAP in detecting hepatic steatosis in patients with chronic liver disease (CLD).
METHODS: A total of 135 patients with CLD who underwent liver biopsy and CAP were consecutively enrolled in this prospective study. The performance of CAP for detection of hepatic steatosis compared with liver biopsy was calculated using area under receiver operating characteristics curves (AUROC). Steatosis was categorized into S0 (<5%), S1 (5-33%), S2 (34-66%) and S3 (>66% of hepatocytes).
RESULTS: Male gender predominated (n = 87, 64%) and the median age was 51 years. The aetiologies of CLD included non-alcoholic fatty liver disease (n = 56, 41.5%) and chronic viral hepatitis because of hepatitis B (n = 47, 34.8%) and C (n = 12, 8.9%). Steatosis repartition was: S0 31.1% (n = 42), S1 43.7% (n = 59), S2 18.5% (n = 25) and S3 6.7% (n = 9) respectively. In the multivariate analysis, steatosis grade and body mass index were independently associated with CAP (all P < 0.001), whereas fibrosis stage and activity grade were not. The AUROCs of CAP were 0.885 for ≥S1 (sensitivity 73.1%, specificity 95.2%), 0.894 for ≥S2 (sensitivity 82.4%, specificity 86.1%) and 0.800 for S3 (sensitivity 77.8%, specificity 84.1%). The optimal cut-off CAP values that maximized the Youden index were 250 dB/m (≥S1), 299 dB/m (≥S2), and 327 dB/m (=S3) respectively.
CONCLUSIONS: Our data showed that CAP had high diagnostic accuracy for detecting hepatic steatosis in patients with CLD and suggested that CAP is also applicable for Asian patients.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Chronic liver disease; controlled attenuation parameter; fatty liver; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; steatosis

Mesh:

Year:  2013        PMID: 24028214     DOI: 10.1111/liv.12282

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  59 in total

Review 1.  Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan(®)).

Authors:  Monica Lupsor-Platon; Radu Badea
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

2.  Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.

Authors:  Wah-Kheong Chan; Nik Raihan Nik Mustapha; Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Sanjiv Mahadeva
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

3.  A Pilot Comparative Study of Quantitative Ultrasound, Conventional Ultrasound, and MRI for Predicting Histology-Determined Steatosis Grade in Adult Nonalcoholic Fatty Liver Disease.

Authors:  Jeremy S Paige; Gregory S Bernstein; Elhamy Heba; Eduardo A C Costa; Marilia Fereirra; Tanya Wolfson; Anthony C Gamst; Mark A Valasek; Grace Y Lin; Aiguo Han; John W Erdman; William D O'Brien; Michael P Andre; Rohit Loomba; Claude B Sirlin
Journal:  AJR Am J Roentgenol       Date:  2017-03-07       Impact factor: 3.959

4.  Factors associated with significant liver fibrosis assessed using transient elastography in general population.

Authors:  Seng Chan You; Kwang Joon Kim; Seung Up Kim; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Won Jae Lee; Kwang-Hyub Han
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

5.  Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis.

Authors:  Giovanna Ferraioli; Carmine Tinelli; Raffaella Lissandrin; Mabel Zicchetti; Mariangela Rondanelli; Guido Perani; Stefano Bernuzzi; Laura Salvaneschi; Carlo Filice
Journal:  Hepatol Int       Date:  2014-09-20       Impact factor: 6.047

6.  Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea.

Authors:  Young Eun Chon; Kyu Sik Jung; Kwang Joon Kim; Dong Jin Joo; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Seung Up Kim
Journal:  Dig Dis Sci       Date:  2014-08-14       Impact factor: 3.199

7.  Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease.

Authors:  Ivana Mikolasevic; Lidija Orlic; Luka Zaputovic; Sanjin Racki; Zlatko Cubranic; Kata Anic; Bosiljka Devcic; Davor Stimac
Journal:  Wien Klin Wochenschr       Date:  2015-04-09       Impact factor: 1.704

8.  Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.

Authors:  Hye Won Lee; Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang Joon Kim; Kwang-Hyub Han
Journal:  Dig Dis Sci       Date:  2017-05-18       Impact factor: 3.199

Review 9.  Clinical applications, limitations and future role of transient elastography in the management of liver disease.

Authors:  Pik Eu Chang; George Boon-Bee Goh; Jing Hieng Ngu; Hiang Keat Tan; Chee Kiat Tan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

10.  Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis.

Authors:  Yuee Wang; Qingqi Fan; Ting Wang; Jia Wen; Hong Wang; Tiansong Zhang
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.